3992-38-9 Usage
Uses
Used in Pharmaceutical Research and Development:
(8alpha,9xi,10alpha,11alpha,13alpha,14xi,17alpha)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl chloroacetate is used as a precursor in the synthesis of steroid-based drugs for various medical applications due to its unique structural features and the potential to create modified steroid derivatives.
Used in Synthesis of Modified Steroid Derivatives:
In the pharmaceutical industry, (8alpha,9xi,10alpha,11alpha,13alpha,14xi,17alpha)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl chloroacetate is used as a key intermediate for the development of novel steroidal compounds with enhanced therapeutic properties, targeting a wide range of medical conditions.
Used in Drug Design and Development:
(8alpha,9xi,10alpha,11alpha,13alpha,14xi,17alpha)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl chloroacetate is utilized as a building block in drug design and development, particularly for creating new medications with improved efficacy, safety, and pharmacokinetic profiles.
Check Digit Verification of cas no
The CAS Registry Mumber 3992-38-9 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,9,9 and 2 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 3992-38:
(6*3)+(5*9)+(4*9)+(3*2)+(2*3)+(1*8)=119
119 % 10 = 9
So 3992-38-9 is a valid CAS Registry Number.
3992-38-9Relevant academic research and scientific papers
Compositions and methods for enhancing drug delivery across and into epithelial tissues
-
Page column 65-67, (2010/02/07)
This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.
